{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:02:39Z","timestamp":1785240159191,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"DOI":"10.7759\/cureus.76733","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T15:12:42Z","timestamp":1735744362000},"source":"Crossref","is-referenced-by-count":1,"title":["Complete Remission of Plasmablastic Lymphoma With Daratumumab and a Mild Regimen of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (Mini-CHOP)"],"prefix":"10.7759","author":[{"given":"Samuel Z","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo JJ","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015, 125:2323-30. 10.1182\/blood-2014-10-567479","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.007","article-title":"Plasmablastic lymphoma. A state-of-the-art review: part 1-epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors, and special populations","volume":"16","author":"Bibas M","year":"2024","unstructured":"Bibas M. Plasmablastic lymphoma. A state-of-the-art review: part 1-epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors, and special populations. Mediterr J Hematol Infect Dis. 2024, 16:e2024007. 10.4084\/MJHID.2024.007","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13981","article-title":"Plasmablastic lymphoma: an update","volume":"44","year":"2022","unstructured":"Plasmablastic lymphoma. an update. Int J Lab Hematol. 2022, 44:1121. 10.1111\/ijlh.13981","journal-title":"Int J Lab Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.014","article-title":"Plasmablastic lymphoma: past, present, and future","volume":"23","author":"Kaur S","year":"2023","unstructured":"Kaur S, Kollimuttathuillam S. Plasmablastic lymphoma: past, present, and future. Clin Lymphoma Myeloma Leuk. 2023, 23:e253-9. 10.1016\/j.clml.2023.05.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.06.036","article-title":"Plasmablastic lymphoma [Article in Spanish]","volume":"147","author":"Fern\u00e1ndez-\u00c1lvarez R","year":"2016","unstructured":"Fern\u00e1ndez-\u00c1lvarez R, Sancho JM, Ribera JM. Plasmablastic lymphoma [Article in Spanish]. Med Clin (Barc). 2016, 147:399-404. 10.1016\/j.medcli.2016.06.036","journal-title":"Med Clin (Barc)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo J","year":"2008","unstructured":"Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008, 83:804-9. 10.1002\/ajh.21250","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-negative plasmablastic lymphoma: not in the mouth","volume":"11","author":"Castillo JJ","year":"2011","unstructured":"Castillo JJ, Winer ES, Stachurski D, et al.. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011, 11:185-9. 10.1016\/j.clml.2011.03.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade F","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, et al.. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011, 12:460-8. 10.1016\/S1470-2045(11)70069-9","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo JJ","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F, et al.. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019, 184:679-82. 10.1111\/bjh.15156","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo JJ","year":"2015","unstructured":"Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015, 169:352-5. 10.1111\/bjh.13300","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164928","article-title":"Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma","volume":"11","author":"Ryu YK","year":"2022","unstructured":"Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE. Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma. J Clin Med. 2022, 11:4928. 10.3390\/jcm11164928","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers M","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, et al.. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011, 186:1840-8. 10.4049\/jimmunol.1003032","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150800","article-title":"Daratumumab plus chemotherapy induces complete responses in a consecutive series of four patients with plasmablastic lymphoma","volume":"138","author":"Ricker EC","year":"2021","unstructured":"Ricker EC, Ryu YK, Amengual JE. Daratumumab plus chemotherapy induces complete responses in a consecutive series of four patients with plasmablastic lymphoma. Blood. 2021, 138:4573. 10.1182\/blood-2021-150800","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000455146","article-title":"A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy","volume":"40","author":"Schmit JM","year":"2017","unstructured":"Schmit JM, DeLaune J, Norkin M, Grosbach A. A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy. Oncol Res Treat. 2017, 40:46-8. 10.1159\/000455146","journal-title":"Oncol Res Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702593","article-title":"Case report: successful management of a refractory plasmablastic lymphoma patient with tislelizumab and lenalidomide","volume":"12","author":"Cheng L","year":"2021","unstructured":"Cheng L, Song Q, Liu M, et al.. Case report: successful management of a refractory plasmablastic lymphoma patient with tislelizumab and lenalidomide. Front Immunol. 2021, 12:702593. 10.3389\/fimmu.2021.702593","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2732-9","article-title":"Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings","volume":"95","author":"Yanamandra U","year":"2016","unstructured":"Yanamandra U, Sahu KK, Jain N, Prakash G, Saikia U, Malhotra P. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings. Ann Hematol. 2016, 95:1715-7. 10.1007\/s00277-016-2732-9","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (review)","volume":"20","author":"Zhang CW","year":"2024","unstructured":"Zhang CW, Wang YN, Ge XL. Lenalidomide use in multiple myeloma (review). Mol Clin Oncol. 2024, 20:7. 10.3892\/mco.2023.2705","journal-title":"Mol Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149019","article-title":"Efficacy of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed diffuse large B cell lymphoma: primary analysis of the Australasian Leukaemia & Lymphoma Group NHL29 study","volume":"138","author":"Verner E","year":"2021","unstructured":"Verner E, Johnston A, Pati N, et al.. Efficacy of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed diffuse large B cell lymphoma: primary analysis of the Australasian Leukaemia & Lymphoma Group NHL29 study. Blood. 2021, 138:304. 10.1182\/blood-2021-149019","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000253","article-title":"Lymphoid neoplasms with plasmablastic differentiation: a comprehensive review and diagnostic approaches","volume":"27","author":"Chen BJ","year":"2020","unstructured":"Chen BJ, Chuang SS. Lymphoid neoplasms with plasmablastic differentiation: a comprehensive review and diagnostic approaches. Adv Anat Pathol. 2020, 27:61-74. 10.1097\/PAP.0000000000000253","journal-title":"Adv Anat Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022639","article-title":"Plasmablastic lymphoma: better refine prognosis","volume":"143","author":"Coppo P","year":"2024","unstructured":"Coppo P, Ricard L. Plasmablastic lymphoma: better refine prognosis. Blood. 2024, 143:101-2. 10.1182\/blood.2023022639","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327316-complete-remission-of-plasmablastic-lymphoma-with-daratumumab-and-a-mild-regimen-of-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-mini-chop","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T15:12:43Z","timestamp":1735744363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327316-complete-remission-of-plasmablastic-lymphoma-with-daratumumab-and-a-mild-regimen-of-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-mini-chop"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.76733","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}